Abstract
Controversy still exists in the relationship between p53 codon72 polymorphism and the risk of endometrial cancer. In order to figure out this inconsistency, database on HuGE Navigator, PubMed and Web of Science about the case-control studies were compiled in the present work. Statistic analysis was performed by STATA 12.0. Total 11 eligible publications were selected in this meta-analysis including 1086 endometrial cancer and 1403 controls. There was no significant relationship between codon72 polymorphism of p53 gene and the risk of endometrial cancer under allele model [Pro versus Arg: OR 0.99, 95% CI (0.87, 1.15)], dominant model [ArgPro+ProPro versus ArgArg: OR 0.88, 95% CI (0.67, 1.15)], recessive model [ProPro versus ArgArg+ArgPro: OR 1.09, 95% CI (0.84, 1.42)] and addictive model [ProPro versus ArgArg: OR 0.97, 95% CI (0.72, 1.29)]. Samples from endometrial tissue with homozygous ArgArg have the increased risk of EC [allele model: OR 0.71, 95% CI (0.53, 0.96); addictive model: OR 0.46, 95% CI (0.24, 0.87)]. This meta-analysis revealed a weak association between the codon72 polymorphism of p53 gene and the risk of endometrial cancer. Women with homozygous Arg72 may be more susceptible to endometrial cancer than others with heterozygotes and homozygous Pro72.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
